论文部分内容阅读
2012年4月,英国药品和健康产品管理局(MHRA)对医务人员和患者发出警告:托伐普坦可导致血钠快速升高和引发严重神经症状[1]。托伐普坦是一种选择性血管加压素V2受体拮抗剂,适用于超容性和等容性低钠血症伴心力衰竭、肝硬化和抗利尿激素分泌异常综合征的治疗。2009年在美国和英国上市;2011年9月在我国上市。托伐普坦说明书已做更新,内容如下:服用托伐普坦的患者,特别是血钠水平低于基线(<120 mmol/L)和有渗透性脱髓
In April 2012, the British Medicines and Health Products Authority (MHRA) warned medical staff and patients that tolvaptan causes a rapid increase in serum sodium and causes serious neurological symptoms [1]. Tolvaptan is a selective vasopressin V2 receptor antagonist for use in the treatment of hypervolemic and isovolumic hyponatremia with heart failure, cirrhosis, and antidiuretic hormone syndrome. Listed in the United States and the United Kingdom in 2009; listed in China in September 2011. The protocol for tolvaptan has been updated to read as follows: Patients taking tolvaptan, especially those with serum sodium levels below baseline (<120 mmol / L) and with osmotic demyelination